文献速递白血病造血干细胞移植与细胞治疗

CAR-T桥接异基因造血干细胞移植治疗难治复发B-ALL

Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
PubMed 文献 · Br J Haematol · 2019-12-23

Although chimeric antigen receptor T cells (CAR-T) targeted at CD19 or CD22 have achieved high complete remission (CR) in refractory/relapsed B-cell acute lymphoblastic leukaemia (B-ALL), it is uncertain if allogeneic haematopoietic stem cell transplantation (allo-HSCT) should be…

要点

  • 该策略在难治复发B-ALL中可行,但需长期随访验证

核心结论

  • CAR-T治疗后快速桥接allo-HSCT可为难治复发B-ALL获得较高无事件生存。

研究设计与样本

  • 预处理采用清髓性减低强度方案,含TBI/氟达拉滨或白消安/氟达拉滨为基础方案。

主要发现

  • CAR-T输注至allo-HSCT中位时间50(34-98)天。
  • 48例可评估病例中16例发生cGVHD,其中3例为广泛型。

临床怎么用

  • 对CAR-T达CR的难治复发B-ALL,可考虑快速桥接allo-HSCT以维持缓解。
  • 采用清髓性RIC方案可能降低GVHD与TRM,即使多数为单倍体供者。

局限性

  • 需长期随访以确认可持续缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although chimeric antigen receptor T cells (CAR-T) targeted at CD19 or CD22 have achieved high complete remission (CR) in refractory/relapsed B-cell acute lymphoblastic leukaemia (B-ALL), it is uncertain if allogeneic haematopoietic stem cell transplantation (allo-HSCT) should be performed after CAR-T therapy to accomplish a sustainable remission. Fifty-two cases with relapsed/refractory B-ALL who underwent allo-HSCT after CR by CD19 or CD22 CAR-T were enrolled. The median time from CAR-T infusion to allo-HSCT was 50 (34-98) days. Myeloablative reduced-intensity conditioning (RIC) with total body irradiation/fludarabine-based or busulfan/fludarabine-based regimens was used. Incidences of grade II-IV acute graft-versus-host disease (aGVHD) and severe aGVHD were 23·1% and 5·8% respectively. Of 48 evaluable cases, 16 developed chronic GVHD (cGVHD) and in three of them the pattern was extensive. With a median follow-up of 334 (41-479) days, one-year overall survival and event-free survival (EFS) were 87·7% and 73·0%. One-year relapse rate and transplant-related mortality (TRM) were 24·7% and 2·2% respectively. With quick bridge to allo-HSCT after CAR-T therapy, high EFS for refractory/relapsed B-ALL has been achieved in this relatively large cohort. Our myeloablative RIC regimens have resulted in low incidences of aGVHD, cGVHD, viral reactivation and very low TRM even majority of transplants from haploidentical donors. Long-term follow-up is warranted.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Chen H, Song Y, et al. Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia. Br J Haematol. 2019. PMID: 31869864. doi:10.1111/bjh.16339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。